News from xencor, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Dec 18, 2014, 08:00 ET

Xencor and Novo Nordisk Enter Discovery Collaboration Using Xencor's XmAb Bispecific and Immune Inhibitor Technologies

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

Dec 06, 2014, 23:00 ET

MorphoSys and Xencor Publish Final Results from Phase 1/2a Trial of MOR208 (XmAb5574) in CLL/SLL at ASH Annual Meeting

 MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) and Xencor Inc. (NASDAQ: XNCR) today announced the publication of final...

Dec 04, 2014, 08:00 ET

Xencor to Present at the 25th Annual Oppenheimer & Co. Healthcare Conference

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

Nov 25, 2014, 08:00 ET

Xencor to Present at the 2014 Deutsche Bank BioFEST Conference

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...

Nov 10, 2014, 16:01 ET

Xencor Reports Third Quarter 2014 Financial Results

 Xencor Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

Nov 06, 2014, 09:09 ET

Xencor Provides Data Updates on XmAb Bispecific Antibody Programs and Announces Presentations at Upcoming American Society of Hematology 2014 Annual Meeting

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...

Nov 04, 2014, 08:00 ET

Xencor to Present at the 2014 Credit Suisse Annual Healthcare Conference

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...

Nov 03, 2014, 08:00 ET

Xencor to Host Third Quarter 2014 Financial Results Webcast and Conference Call

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

Oct 28, 2014, 16:00 ET

Xencor Renegotiates XmAb®5871 Agreement with Amgen; Regains All Rights and Plans Clinical Development in Rare Autoimmune Disease

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

Sep 02, 2014, 08:00 ET

Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

Aug 05, 2014, 08:00 ET

Xencor to Present at Wedbush Securities 2014 Life Sciences Management Access Conference

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...

Jul 31, 2014, 16:01 ET

Xencor Reports Second Quarter 2014 Financial Results

Xencor Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

Jul 24, 2014, 08:00 ET

Xencor to Host Second Quarter 2014 Financial Results Webcast and Conference Call

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

Jul 15, 2014, 08:00 ET

Xencor Appoints Kurt Gustafson to Board of Directors; Promotes John Desjarlais to Chief Scientific Officer

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

May 28, 2014, 08:00 ET

Xencor Initiates Phase 1 Study of XmAb7195 for Asthma

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

May 22, 2014, 08:00 ET

Xencor to Present at Jefferies 2014 Global Healthcare Conference

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

May 15, 2014, 08:00 ET

Xencor Presents Study Comparing XmAb7195 to Omalizumab at the American Thoracic Society 2014 International Conference

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

May 14, 2014, 16:01 ET

Xencor Reports First Quarter 2014 Financial Results

 Xencor Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

May 07, 2014, 08:00 ET

Xencor to Host First Quarter 2014 Financial Results Webcast and Conference Call

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

Apr 29, 2014, 08:00 ET

Xencor, Inc. to Present at Deutsche Bank 39th Annual Health Care Conference

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...